<DOC>
	<DOCNO>NCT00457171</DOCNO>
	<brief_summary>The aim double blind , placebo control , study evaluate activity consistent efficacy provide 14 day administration GI270384X , provide preliminary pharmacokinetics safety/tolerability 14 day administration GI270384X patient mild moderate active ulcerative colitis ( UC ) .</brief_summary>
	<brief_title>GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Inclusion criterion : Females childbearing nonchildbearing potential Subjects relapse ( relapse = 6 week ago ; least second episode ) mild moderate UC ( score 4 11 MTWI Screening endoscopy score = 2 ) . Diagnosis UC originally must establish sigmoidoscopy colonoscopy , compatible histology . As confirmed sign informed consent , subject must understand able , willing likely fully comply study procedure restriction Exclusion criterion : Subjects severe UC accord MTWI ( score &gt; 11 ) subject relapse &gt; 6 week . Subjects eligible study Crohn 's Disease , proctitis ( extent inflammation = 15 cm ) , bleed disorder , active ulcer disease . Positive stool culture enteric pathogen ( include Salmonella , Shigella , Yersinia , Aeromonas , Plesiomonas Campylobacter ) . Presence Clostridium difficile toxin present ova parasite detect microscopy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>GI-270384 colitis patient ECAM oral</keyword>
</DOC>